ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Sevocalm 100% v/v Inhalation vapour, liquid for dogs.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Active substance:
Sevoflurane 100% v/v.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM
Inhalation vapour, liquid.
Clear, colourless liquid.

4. CLINICAL PARTICULARS
4.1 Target species
Dogs.

4.2 Indications for use, specifying the target species
For the induction and maintenance of anaesthesia.

4.3 Contraindications
Do not use in dogs with known hypersensitivity to sevoflurane or other halogenated anaesthetic agents.
Do not use in pregnant and lactating bitches (see section 4.7).
Do not use in dogs with a known or suspected genetic susceptibility to malignant hyperthermia.
Do not use in dogs less than 12 weeks of age.

4.4 Special warnings for each target species
None.

4.5 Special precautions for use
Special precautions for use in animals

Halogenated volatile anaesthetics can react with dry carbon dioxide (CO₂) absorbents to produce carbon monoxide (CO) that may result in elevated levels of carboxyhaemoglobin in some dogs. In order to minimise this reaction in rebreathing anaesthetic circuits, Sevocalm should not be passed through soda lime or barium hydroxide that has been allowed to dry out.

The exothermic reaction that occurs between inhalation agents (including sevoflurane) and CO₂ absorbents is increased when the CO₂ absorbent becomes desiccated, such as after an extended period of dry gas flow through the CO₂ absorbent canisters. Rare cases of excessive heat production, smoke and/or fire in the anaesthetic machine have been reported during the use of a desiccated CO₂ absorbent and sevoflurane. An unusual decrease in the expected depth of anaesthesia compared to the vaporiser setting may indicate excessive heating of the CO₂ absorbent canister.
If it is suspected that the CO₂ absorbent may be desiccated, it must be replaced. The colour indicator of most CO₂ absorbents does not necessarily change as a result of desiccation. Therefore, the lack of significant colour change should not be taken as an assurance of adequate hydration. CO₂ absorbents should be replaced routinely regardless of the state of the colour indicator.

1,1,3,3,3-pentafluoro-2-(fluoromethoxy)propene (C₄H₂F₆O), also known as Compound A, is produced when sevoflurane interacts with soda lime or barium hydroxide. Reaction with barium hydroxide results in a greater production of Compound A than does the reaction with soda lime. Its concentration in a circle absorber system increases with increasing sevoflurane concentrations and with decreasing fresh gas flow rates. Sevoflurane degradation in soda lime has been shown to increase with temperature. Since the reaction of carbon dioxide with absorbents is exothermic, this temperature increase will be determined by the quantities of CO₂ absorbed, which in turn will depend on fresh gas flow in the anaesthetic circle system, metabolic status of the dog and ventilation. Although Compound A is a dose-dependent nephrotoxin in rats, the mechanism of this renal toxicity is unknown. Long duration, low-flow sevoflurane anaesthesia should be avoided due to the risks of Compound A accumulation.

During maintenance of anaesthesia, increasing the concentration of sevoflurane produces a dose dependent decrease in blood pressure. Due to sevoflurane's low solubility in blood, these haemodynamic changes may occur more rapidly than with other volatile anaesthetics. Arterial blood pressure should be monitored at frequent intervals during sevoflurane anaesthesia. Facilities for artificial ventilation, oxygen enrichment and circulatory resuscitation should be immediately available. Excessive decreases in blood pressure or respiratory depression may be related to the depth of anaesthesia and may be corrected by decreasing the inspired concentration of sevoflurane. The low solubility of sevoflurane also facilitates rapid elimination by the lungs. The nephrotoxic potential of certain NSAIDs, when used in the perioperative period, may be exacerbated by hypotensive episodes during sevoflurane anaesthesia. In order to maintain renal blood flow, prolonged episodes of hypotension (mean arterial pressure below 60 mmHg) should be avoided in dogs during sevoflurane anaesthesia.

If malignant hyperthermia develops, the anaesthetic supply should be interrupted immediately and 100% oxygen administered using fresh anaesthetic hoses and a rebreathing bag. Appropriate treatment should readily be instituted.

Compromised or debilitated dogs
Doses of sevoflurane may need adjustment for geriatric or debilitated dogs. Doses required for maintenance anaesthesia may need to be reduced by approximately 0.5% in geriatric dogs (i.e. 2.8% to 3.1% in premedicated geriatric dogs and 3.2 to 3.3% in unpremedicated geriatric dogs). Limited clinical experience in administering sevoflurane to dogs with renal, hepatic and cardiovascular insufficiency suggests that sevoflurane may be safely used in these conditions. However, it is recommended that such animals be monitored carefully during sevoflurane anaesthesia.

Sevoflurane may cause a small increase in intracranial pressure (ICP) under conditions of normocapnia. In dogs with head injuries or other conditions placing them at risk from increased ICP, it is recommended that hypocapnia be induced by means of controlled hyperventilation as a means of preventing changes in ICP.

Special precautions to be taken by the person administering the veterinary medicinal product to animals
In order to minimise exposure to sevoflurane vapour, the following recommendations are made:

- Use a cuffed endotracheal tube when possible for the administration of Sevocalm during maintenance anaesthesia.
- Avoid using masking procedures for prolonged induction and maintenance of general anaesthesia.
- Ensure that operating rooms and animal recovery areas are provided with adequate ventilation or scavenging systems to prevent the accumulation of anaesthetic vapour.
• All scavenging/extraction systems must be adequately maintained.
• Pregnant and breast-feeding women should not have any contact with the product and should avoid operating rooms and animal recovery areas.
• Care should be taken when dispensing Sevocalm, with immediate removal of any spillage.
• Do not inhale the vapour directly.
• Avoid contact by mouth.
• Halogenated anaesthetic agents may induce liver damage. This is an idiosyncratic response very occasionally seen after repeated exposure.
• From an environmental point of view, it is considered good practice to use charcoal filters with scavenging equipment.

Direct exposure to eyes may result in mild irritation. If eye exposure occurs, the eye should be flushed with plenty of water for 15 minutes. Medical attention should be sought if irritation persists.

In case of accidental contact with the skin, wash the affected area with abundant water.

Symptoms of human overexposure (inhalation) to sevoflurane vapour include respiratory depression, hypotension, bradycardia, shivering, nausea and headache. If these symptoms occur, the individual should be removed from the source of exposure and medical attention sought.

**Advice to doctors:** Maintain a patent airway and give symptomatic and supportive treatment.

### 4.6 Adverse reactions (frequency and seriousness)

The most frequently reported adverse reactions associated with Sevocalm administration were hypotension, followed by tachypnoea, muscle tenseness, excitation, apnoea, muscle fasciculations and emesis.

Sevoflurane causes dose-dependent respiratory depression, therefore respiration should be closely monitored during sevoflurane anaesthesia and the inspired concentration of sevoflurane adjusted accordingly.

The use of some anaesthetic regimens that include sevoflurane may result in bradycardia that is reversible with anticholinergics.

Infrequent adverse reactions include paddling, retching, salivation, cyanosis, premature ventricular contractions and excessive cardiopulmonary depression.

Transient elevations in aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), bilirubin and white blood cell counts may occur with sevoflurane, as with the use of other halogenated anaesthetic agents.

Hypotension during sevoflurane anaesthesia may result in decreased renal blood flow.

The possibility of sevoflurane triggering episodes of malignant hyperthermia in susceptible dogs cannot be ruled out.

The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).

### 4.7 Use during pregnancy, lactation or lay
Do not use during pregnancy and lactation because the safety of the veterinary medicinal product has not been established during pregnancy and lactation. However, there is limited clinical experience of the use of sevoflurane, after propofol induction, in bitches undergoing caesarean section, without any ill effects being detected in either the bitch or the puppies. Use only according to the risk/benefit assessment of the responsible veterinarian.

4.8 Interaction with other medicinal products and other forms of interaction

**Intravenous Anaesthetics:**
Sevoflurane administration is compatible with the intravenous barbiturates and propofol. The concurrent administration of thiopental, however, may slightly increase sensitivity to adrenaline induced cardiac arrhythmias.

**Benzodiazepines and Opioids:**
Sevoflurane administration is compatible with benzodiazepines and opioids commonly used in veterinary practice. In common with other inhalational anaesthetics, the MAC of sevoflurane is reduced by the concurrent administration of benzodiazepines and opioids.

**Phenothiazines and alpha-2-agonists:**
Sevoflurane is compatible with phenothiazines and alpha-2-agonists commonly used in veterinary practice. Alpha-2-agonists have an anaesthetic sparing effect and therefore the dose of sevoflurane should be reduced accordingly. Limited data are available on the effects of the highly potent alpha-2-agonists (medetomidine and romifidine) as premedication. Therefore they should be used with caution. Bradycardia may develop when alpha-2-agonists are used with sevoflurane. Bradycardia can be reversed by the administration of anticholinergics.

**Anticholinergics:**
Studies using sevoflurane anaesthetic protocols that included atropine or glycopyrrolate as premedicants showed these anticholinergics to be compatible with sevoflurane in dogs.

In a laboratory study, the use of an acepromazine/oxymorphone/thiopental/sevoflurane anaesthetic regimen resulted in prolonged recoveries in all the dogs treated, compared to recoveries in dogs anaesthetised with sevoflurane alone.

The use of sevoflurane with nondepolarising muscle relaxants has not been evaluated in dogs. However, in humans the use of sevoflurane increases both the intensity and duration of neuromuscular blockade induced by nondepolarising muscle relaxants.

4.9 Amounts to be administered and administration route

**Inhalation use.**

**Inspired Concentration:**
Sevocalm should be administered via a vaporiser specifically calibrated for use with sevoflurane so that the concentration delivered can be accurately controlled. Sevocalm contains no stabiliser and does not affect the calibration or operation of these vaporisers in any way. The administration of sevoflurane must be individualised based on the dog’s response.

**Premedication:**
The necessity for and choice of premedication is left to the discretion of the veterinarian. Preanaesthetic doses for premedicants may be lower than the label directions for their use as a single medication.

**Induction of anaesthesia:**
For mask induction using sevoflurane, inspired concentrations of 5 to 7% sevoflurane with oxygen are employed to induce surgical anaesthesia in the healthy dog. These concentrations can be expected to produce surgical anaesthesia within 3 to 14 minutes and may be set initially, or may be achieved
gradually over the course of 1 to 2 minutes. The use of premedicants does not affect the concentration of sevoflurane required for induction.

**Maintenance of anaesthesia:**
Sevoflurane may be used for maintenance anaesthesia following mask induction with sevoflurane or following induction with injectable agents. The concentration of sevoflurane necessary to maintain anaesthesia is less than that required for induction.

Surgical levels of anaesthesia in the healthy dog may be maintained with inhaled concentrations of 3.3 to 3.6% in the presence of premedication. In the absence of premedication, inhaled concentrations of sevoflurane in the range 3.7 to 3.8% will provide surgical levels of anaesthesia in the healthy dog.

The presence of surgical stimulation may require an increase in the concentration of sevoflurane.

The use of injectable induction agents without premedication has little effect on the concentrations of sevoflurane required for maintenance.

Anaesthetic regimens that include opioid, alpha-2-agonist, benzodiazepine or phenothiazine premedication will allow the use of lower sevoflurane maintenance concentrations.

**4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

Sevocalm overdose may result in profound respiratory depression. Therefore, respiration must be monitored closely and supported when necessary with supplementary oxygen and/or assisted ventilation.

In cases of severe cardiopulmonary depression, administration of sevoflurane should be discontinued, the existence of a patent airway ensured, and assisted or controlled ventilation with pure oxygen initiated. Cardiovascular depression should be treated with plasma expanders, pressor agents, antiarrhythmic agents or other appropriate techniques.

Due to sevoflurane's low solubility in blood, increasing the concentration may result in rapid haemodynamic changes (dose-dependent decreases in blood pressure) compared to other volatile anaesthetics. Excessive decreases in blood pressure or respiratory depression may be corrected by decreasing or discontinuing the inspired concentration of sevoflurane.

**4.11 Withdrawal period(s)**

Not applicable.

**5. PHARMACOLOGICAL PROPERTIES**

Pharmacotherapeutic group: inhalation anaesthetic, ATCvet code: QN 01AB08

**5.1 Pharmacodynamic properties**

Sevoflurane is an inhalational anaesthetic agent, having a light odour, for induction and maintenance of general anaesthesia. The Minimum Alveolar Concentration (MAC) of sevoflurane in dogs is 2.36%. Multiples of MAC are used as a guide for surgical levels of anaesthesia, which are typically 1.3 to 1.5 times the MAC value.

Sevoflurane produces unconsciousness by its action on the central nervous system. Sevoflurane produces only modest increases in cerebral blood flow and metabolic rate, and has little or no ability to potentiate seizures. Sevoflurane may increase intracranial pressure at concentrations of 2.0 MAC and above under normal partial pressures of carbon dioxide (normocapnia), but intracranial pressure has been shown to remain within normal range at sevoflurane concentrations of up to 1.5 MAC if
hypocapnia is induced by hyperventilation.

Sevoflurane has a variable effect on heart rate, which tends to increase from baseline at low MAC and fall back with increasing MAC. Sevoflurane causes systemic vasodilation and produces dose dependent decreases in mean arterial pressure, total peripheral resistance, cardiac output and possibly the strength of myocardial contraction and speed of myocardial relaxation.

Sevoflurane has a depressive effect on respiration characterised by a fall in ventilation frequency. Respiratory depression may lead to respiratory acidosis and respiratory arrest (at sevoflurane concentrations of 2.0 MAC and above) in spontaneously breathing dogs.

Concentrations of sevoflurane below 2.0 MAC result in a small net increase in total liver blood flow. Hepatic oxygen delivery and consumption were not significantly altered at concentrations up to 2.0 MAC.

Sevoflurane administration adversely affects the autoregulation of renal blood flow in dogs. As a result, renal blood flow falls in a linear fashion with increasing hypotension in sevoflurane anaesthetised dogs. Nevertheless, renal oxygen consumption, and hence renal function, are preserved at mean arterial pressures above 40 mmHg.

5.2 Pharmacokinetic particulars

A minimal amount of sevoflurane is required to be dissolved in the blood before the alveolar partial pressure is in equilibrium with the arterial partial pressure because of the low solubility of sevoflurane in blood (blood/gas partition coefficient at 30 °C is 0.63 to 0.69). During sevoflurane induction, there is a rapid increase in alveolar concentration towards the inspired concentration, with the ratio of inspired to end-tidal concentration of sevoflurane reaching a value of 1 within 10 minutes. Anaesthetic induction is correspondingly rapid and the depth of anaesthesia changes rapidly with changes in anaesthetic concentration.

Sevoflurane is metabolised to a limited extent in the dog (1 to 5%). The principle metabolites are hexafluoroisopropanol (HFIP) with release of inorganic fluoride and CO₂. Fluoride ion concentrations are influenced by the duration of anaesthesia and the concentration of sevoflurane. Once formed, HFIP is rapidly conjugated with glucuronic acid and eliminated as a urinary metabolite. No other metabolic pathways for sevoflurane have been identified. In dogs exposed to 4% sevoflurane for 3 hours, mean peak maximum serum fluoride concentrations of 20.0 ± 4.8 µmol/l have been observed after 3 hours of anaesthesia. Serum fluoride fell quickly after anaesthesia ended and had returned to baseline by 24 hours post-anaesthesia.

The elimination of sevoflurane is biphasic in nature, with an initial rapid phase and a second, slower phase. Parent compound (the dominant fraction) is eliminated via the lungs. The half-life for the slow elimination phase is approximately 50 minutes. Elimination from blood is largely complete within 24 hours. The elimination time from adipose tissue is more prolonged than from the brain.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

None.

6.2 Incompatibilities

None known.

6.3 Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 3 years

6.4. Special precautions for storage

Do not store above 25 °C.
Do not refrigerate.
Keep the bottle tightly closed.

6.5. Nature and composition of immediate packaging

250 ml Type III amber glass bottle with a yellow collar on the neck, sealed with a poly-seal cap, and secured with PET film.

Cardboard box containing either 1 or 6 bottles.

Not all pack sizes may be marketed.

6.6. Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Chanelle Pharmaceuticals Manufacturing Ltd.,
Loughrea,
Co. Galway,
IRELAND

8. MARKETING AUTHORISATION NUMBER(S)

EU/2/16/196/001–002

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation:

10. DATE OF REVISION OF THE TEXT


PROHIBITION OF SALE, SUPPLY AND/OR USE

Not applicable.
ANNEX II

A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. STATEMENT OF THE MRLs
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

Chanelle Pharmaceuticals Manufacturing Ltd
Loughrea
Co. Galway
IRELAND

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Veterinary medicinal product subject to prescription.

C. STATEMENT OF THE MRLs

Not applicable.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
<table>
<thead>
<tr>
<th>PARTICULARS TO APPEAR ON THE OUTER PACKAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carton box</td>
</tr>
</tbody>
</table>

1. **NAME OF THE VETERINARY MEDICINAL PRODUCT**

Sevocalm 100% v/v Inhalation vapour, liquid for dogs.
sevoflurane

2. **STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Sevoflurane 100% v/v

3. **PHARMACEUTICAL FORM**

Inhalation vapour, liquid

4. **PACKAGE SIZE**

250 ml
6 x 250 ml

5. **TARGET SPECIES**

Dogs

6. **INDICATION(S)**

For induction and maintenance of anaesthesia.

7. **METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.
Administer by inhalation using a vaporiser calibrated for sevoflurane.

8. **WITHDRAWAL PERIOD**

9. **SPECIAL WARNING(S), IF NECESSARY**

Do not use in dogs with known hypersensitivity to sevoflurane or other halogenated anaesthetic agents.
Do not use in pregnant and lactating bitches.
Do not use in dogs with a known or suspected genetic susceptibility to malignant hyperthermia.
Do not use in dogs less than 12 weeks of age.

For operator warnings - read the package leaflet before use.
10. **EXPIRY DATE**

EXP {month/year}

11. **SPECIAL STORAGE CONDITIONS**

Do not store above 25 °C.
Do not refrigerate.
Keep the bottle tightly closed.

12. **SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

13. **THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

14. **THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

15. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Ltd.,
Loughrea,
Co. Galway,
IRELAND

16. **MARKETING AUTHORISATION NUMBER(S)**

EU/2/16/196/001 (250 ml)
EU/2/16/196/002 (6 x 250 ml)

17. **MANUFACTURER'S BATCH NUMBER**

BN{number}
PARTICULARS TO APPEAR ON THE INNER PACKAGE

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Sevocalm 100% v/v Inhalation vapour, liquid for dogs. sevoflurane

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

100% v/v sevoflurane

3. PHARMACEUTICAL FORM

Inhalation vapour, liquid

4. PACKAGE SIZE

250 ml

5. TARGET SPECIES

Dogs

6. INDICATION(S)

For induction and maintenance of anaesthesia.

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

8. WITHDRAWAL PERIOD


9. SPECIAL WARNING(S), IF NECESSARY

Do not use in pregnant and lactating bitches or in dogs less than 12 weeks of age. For operator warnings – read the package leaflet before use.

10. EXPIRY DATE

EXP {month/year}
11. SPECIAL STORAGE CONDITIONS

Do not store above 25 °C.
Do not refrigerate.
Keep the bottle tightly closed.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Read the package leaflet before use.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Chanelle Pharmaceuticals Manufacturing Ltd.,
Loughrea,
Co. Galway,
IRELAND

16. MARKETING AUTHORISATION NUMBER(S)

EU/2/16/196/001 (250 ml)
EU/2/16/196/002 (6 x 250 ml)

17. MANUFACTURER’S BATCH NUMBER

BN{number}
B. PACKAGE LEAFLET
1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder and manufacturer responsible for batch release:

Chanelle Pharmaceuticals Manufacturing Ltd.,
Loughrea,
Co. Galway,
IRELAND

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Sevocalm 100% v/v Inhalation vapour, liquid for dogs.
sevoflurane

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

100% v/v sevoflurane.

4. INDICATION(S)

For the induction and maintenance of anaesthesia.

5. CONTRAINDICATIONS

Do not use in dogs with known hypersensitivity to sevoflurane or other halogenated anaesthetic agents.
Do not use in pregnant and lactating bitches (see section 12).
Do not use in dogs with a known or suspected genetic susceptibility to malignant hyperthermia.
Do not use in dogs less than 12 weeks of age.

6. ADVERSE REACTIONS

The most frequently reported adverse reactions associated with Sevocalm administration were hypotension, followed by tachypnoea, muscle tenseness, excitation, apnoea, muscle fasciculations and emesis.

Sevoflurane causes dose-dependent respiratory depression, therefore respiration should be closely monitored during sevoflurane anaesthesia and the inspired concentration of sevoflurane adjusted accordingly.

The use of some anaesthetic regimens that include sevoflurane may result in bradycardia that is reversible with anticholinergics.

Infrequent adverse reactions include paddling, retching, salivation, cyanosis, premature ventricular contractions and excessive cardiopulmonary depression.
Transient elevations in aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), bilirubin and white blood cell count may occur with sevoflurane, as with the use of other halogenated anaesthetic agents.

Hypotension during sevoflurane anaesthesia may result in decreased renal blood flow.

The possibility of sevoflurane triggering episodes of malignant hyperthermia in susceptible dogs cannot be ruled out.

The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).

If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon.

7. TARGET SPECIES

Dogs.

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Inhalation use.

**Inspired concentration:**
Sevocalm should be administered via a vaporiser specifically calibrated for use with sevoflurane so that the concentration delivered can be accurately controlled. Sevocalm contains no stabiliser and does not affect the calibration or operation of these vaporisers in any way. The administration of sevoflurane must be individualised based on the dog’s response.

**Premedication:**
The necessity for and choice of premedication is left to the discretion of the veterinarian. Preanaesthetic doses for premedicants may be lower than the label directions for their use as a single medication.

**Induction of anaesthesia:**
For mask induction using sevoflurane, inspired concentrations of 5 to 7% sevoflurane with oxygen are employed to induce surgical anaesthesia in the healthy dog. These concentrations can be expected to produce surgical anaesthesia in 3 to 14 minutes and may be set initially, or may be achieved gradually over the course of 1 to 2 minutes. The use of premedicants does not affect the concentration of sevoflurane required for induction.

**Maintenance of anaesthesia:**
Sevoflurane may be used for maintenance anaesthesia following mask induction using sevoflurane or following induction with injectable agents. The concentration of sevoflurane necessary to maintain anaesthesia is much less than that required for induction.

Surgical levels of anaesthesia in the healthy dog may be maintained with inhaled concentrations of 3.3 to 3.6% in the presence of premedication. In the absence of premedication, inhaled concentrations of sevoflurane in the range of 3.7 to 3.8% will provide surgical levels of anaesthesia in the healthy dog.
The presence of surgical stimulation may require an increase in the concentration of sevoflurane. The use of injectable induction agents without premedication has little effect on the concentrations of sevoflurane required for maintenance. Anaesthetic regimens that include opioid, alpha-2-agonist, benzodiazepine or phenothiazine premedication will allow the use of lower sevoflurane maintenance concentrations.

9. ADVICE ON CORRECT ADMINISTRATION

For inhalation use only, using a suitable carrier gas. Sevocalm should be administered via a vaporiser specifically calibrated for use with sevoflurane so that the concentration delivered can be accurately controlled. Sevocalm contains no stabiliser and does not affect the calibration or operation of these vaporisers.

The administration of general anaesthesia must be individualised based on the dog's response.

Interaction with other veterinary medicinal products and other forms of interaction

Intravenous Anaesthetics:

Sevoflurane administration is compatible with the intravenous barbiturates and propofol. The concurrent administration of thiopental, however, may slightly increase sensitivity to adrenaline induced cardiac arrhythmias.

Benzodiazepines and Opioids:

Sevoflurane administration is compatible with benzodiazepines and opioids commonly used in veterinary practice. In common with other inhalational anaesthetics, the minimum alveolar concentration (MAC) of sevoflurane is reduced by the concurrent administration of benzodiazepines and opioids.

Phenothiazines and alpha-2-agonists:

Sevoflurane is compatible with phenothiazines and alpha-2-agonists commonly used in veterinary practice. Alpha-2-agonists have an anaesthetic sparing effect and therefore the dose of sevoflurane should be reduced accordingly. Limited data are available on the effects of the highly potent alpha-2-agonists (medetomidine and romifidine) as premedication. Therefore they should be used with caution. Bradycardia may develop when alpha-2-agonists are used with sevoflurane. Bradycardia can be reversed by the administration of anticholinergics.

Anticholinergics:

Studies using sevoflurane anaesthetic protocols that included atropine or glycopyrrolate as premedicants showed these anticholinergics to be compatible with sevoflurane in dogs.

In a laboratory study, the use of an acepromazine/oxymorphone/thiopental/sevoflurane anaesthetic regimen resulted in prolonged recoveries in all the dogs treated, compared to recoveries in dogs anaesthetised with sevoflurane alone.

The use of sevoflurane with nondepolarising muscle relaxants has not been evaluated in dogs. However, in humans the use of sevoflurane increases both the intensity and duration of neuromuscular blockade induced by nondepolarising muscle relaxants.

10. WITHDRAWAL PERIOD

Not applicable.
11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Do not store above 25 °C.
Do not refrigerate.
Keep the bottle tightly closed.
Do not use this veterinary medicinal product after the expiry date which is stated on the label.

12. SPECIAL WARNING(S)

Special precautions for use in animals:

Halogenated volatile anaesthetics can react with desiccated carbon dioxide (CO₂) absorbents to produce carbon monoxide (CO) that may result in elevated levels of carboxyhaemoglobin in some dogs. In order to minimise this reaction in rebreathing anaesthetic circuits, Sevocalm should not be passed through soda lime or barium hydroxide that has been allowed to dry out.

The exothermic reaction that occurs between sevoflurane and CO₂ absorbents is increased when the CO₂ absorbent becomes desiccated (dried out), such as after an extended period of dry gas flow through the CO₂ absorbent canisters. Rare cases of excessive heat production, smoke and/or fire in the anaesthetic machine have been reported during the use of a desiccated CO₂ absorbent and sevoflurane. An unusual decrease in the expected depth of anaesthesia compared to the vaporiser setting may indicate excessive heating of the CO₂ absorbent canister.

If it is suspected that the CO₂ absorbent may be desiccated, it must be replaced. The colour indicator of most CO₂ absorbents does not necessarily change as a result of desiccation. Therefore, the lack of significant colour change should not be taken as an assurance of adequate hydration. CO₂ absorbents should be replaced routinely regardless of the state of the colour indicator.

1,1,3,3,3-pentafluoro-2-(fluoromethoxy)propene (C₄H₂F₆O), also known as Compound A, is produced when sevoflurane interacts with soda lime or barium hydroxide. Reaction with barium hydroxide results in a greater production of Compound A than does the reaction with soda lime. Its concentration in a circle absorber system increases with increasing sevoflurane concentrations and with decreasing fresh gas flow rates. Sevoflurane degradation in soda lime has been shown to increase with temperature. Since the reaction of carbon dioxide with absorbents is exothermic, this temperature increase will be determined by the quantities of CO₂ absorbed, which in turn will depend on fresh gas flow in the anaesthetic circle system, metabolic status of the dog and ventilation. Although Compound A is a dose-dependent nephrotoxin in rats, the mechanism of this renal toxicity is unknown. Long duration, low-flow sevoflurane anaesthesia should be avoided due to the risks of Compound A accumulation.

During the maintenance of anaesthesia, increasing the concentration of sevoflurane produces a dose dependent decrease in blood pressure. Due to sevoflurane’s low solubility in blood, these haemodynamic changes may occur more rapidly than with other volatile anaesthetics. Arterial blood pressure should be monitored at frequent intervals during sevoflurane anaesthesia. Facilities for artificial ventilation, oxygen enrichment and circulatory resuscitation should be immediately available. Excessive decreases in blood pressure or respiratory depression may be related to the depth of anaesthesia and may be corrected by decreasing the inspired concentration of sevoflurane. The low solubility of sevoflurane also facilitates rapid elimination by the lungs. The nephrotoxic potential of certain NSAIDs, when used in the perioperative period, may be exacerbated by hypotensive episodes during sevoflurane anaesthesia. In order to preserve renal blood flow, prolonged episodes of hypotension (mean arterial pressure below 60 mmHg) should be avoided in dogs during sevoflurane anaesthesia.
The use of sevoflurane with nondepolarising muscle relaxants has not been evaluated in dogs. The use of sevoflurane in humans increases both the intensity and duration of neuromuscular blockade induced by nondepolarising muscle relaxants.

Sevoflurane may trigger episodes of malignant hyperthermia in susceptible dogs. If malignant hyperthermia develops, the anaesthetic supply should be interrupted immediately and 100% oxygen administered using fresh anaesthetic hoses and a rebreathing bag. Appropriate treatment should readily be instituted.

**Compromised or debilitated dogs:**
Doses of sevoflurane may need adjustment for geriatric or debilitated dogs. Doses required for maintenance anaesthesia may need to be reduced by approximately 0.5% in geriatric dogs (i.e. 2.8 to 3.1% in premedicated geriatric dogs and 3.2 to 3.3% in unpremedicated geriatric dogs). Limited clinical experience in administering sevoflurane to dogs with renal, hepatic and cardiovascular insufficiency suggests that sevoflurane may be safely used in these conditions. However, it is recommended that such animals be monitored carefully during sevoflurane anaesthesia.

Sevoflurane may cause a small increase in intracranial pressure (ICP) under conditions of normocapnia. In dogs with head injuries or other conditions placing them at risk from increased ICP, it is recommended that hypocapnia be induced by means of controlled hyperventilation as a means of preventing changes in ICP.

**Pregnancy and lactation:**
Do not use during pregnancy and lactation because the safety of the veterinary medicinal product has not been established during pregnancy and lactation. However, there is limited clinical experience of the use of sevoflurane, after propofol induction, in bitches undergoing caesarean section, without any ill effects being detected in either the bitch or the puppies. Use only according to the risk/benefit assessment of the responsible veterinarian.

**Overdose (symptoms, emergency procedures, antidotes):**
Sevocalm overdose may result in profound respiratory depression. Therefore, respiration must be monitored closely and supported when necessary with supplementary oxygen and/or assisted ventilation.

In cases of severe cardiopulmonary depression, discontinue sevoflurane administration, ensure the existence of a patent airway and initiate assisted or controlled ventilation with pure oxygen. Cardiovascular depression should be treated with plasma expanders, pressor agents, antiarrhythmic agents or other appropriate techniques.

Due to sevoflurane’s low solubility in blood, increasing the concentration may result in rapid haemodynamic changes (dose-dependent decreases in blood pressure) compared to other volatile anaesthetics. Excessive decreases in blood pressure or respiratory depression may be corrected by decreasing or discontinuing the inspired concentration of sevoflurane.

**Special precautions to be taken by the person administering the veterinary medicinal product to animals:**
In order to minimise exposure to sevoflurane vapour, the following recommendations are made:

- Use a cuffed endotracheal tube when possible for the administration of Sevocalm during maintenance anaesthesia.
- Avoid using masking procedures for prolonged induction and maintenance of general anaesthesia.
- Ensure that operating rooms and animal recovery areas are provided with adequate ventilation or scavenging systems to prevent the accumulation of anaesthetic vapour.
- All scavenging/extraction systems must be adequately maintained.
Pregnant and breast-feeding women should not have any contact with the product and should avoid operating rooms and animal recovery areas.

Care should be taken when dispensing Sevocalm, with immediate removal of any spillage.

Do not inhale the vapour directly.

Avoid contact by mouth.

Halogenated anaesthetic agents may induce liver damage. This is an idiosyncratic response very occasionally seen after repeated exposure.

From an environmental point of view, it is considered good practice to use charcoal filters with scavenging equipment.

Direct exposure to eyes may result in mild irritation. If eye exposure occurs, wash with plenty of water for 15 minutes. Seek medical attention if irritation persists.

In case of accidental contact with the skin, wash the affected area with abundant water.

Symptoms of human overexposure (inhalation) to sevoflurane vapours include respiratory depression, hypotension, bradycardia, shivering, nausea and headache. If these symptoms occur, remove the individual from the source of exposure and seek medical attention.

Advice to doctors:

Maintain a patent airway and give symptomatic and supportive treatment.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

Medicines should not be disposed of via wastewater or household waste.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.

15. OTHER INFORMATION

For animal treatment only.

250 ml amber glass bottle with a yellow collar on the neck, sealed with a poly-seal cap, and secured with PET film.

Cardboard box containing either 1 or 6 bottles.

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

Belgie/Belgique/Belgien
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland

Luxembourg/Luxemburg
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Република България
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Tel: +353 91 841788

Магарошзág
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Tel.: + 353 91 841788

Česká republika
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Tel: + 353 91 841788

Malta
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Tel: + 353 91 841788

Danmark
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Tlf: + 353 91 841788

Nederland
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Tel: + 353 91 841788

Deutschland
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Tel: + 353 91 841788

Norge
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Tlf: + 353 91 841788

Česká republika
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Tel: + 353 91 841788

Österreich
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Tel: + 353 91 841788

Ελλάδα
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Τηλ.: + 353 91 841788

Polska
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Tel.: + 353 91 841788

España
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Tel: + 353 91 841788

Portugal
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Tel: + 353 91 841788

France
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Tél: + 353 91 841788

România
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Tel: + 353 91 841788
Ireland
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Tel: + 353 91 841788

Slovenija
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Tel: + 353 91 841788

Ísland
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Sími: + 353 91 841788

Slovenská republika
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Tel: + 353 91 841788

Italia
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Tel: + 353 91 841788

Suomi/Finland
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Puh/Tel: + 353 91 841788

Κύπρος
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Τηλ: + 353 91 841788

Sverige
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Tel: + 353 91 841788

Latvija
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Tel: + 353 91 841788

Lietuva
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Tel: + 353 91 841788

United Kingdom
Chanelle Vet UK Ltd
1 High Street
Hungerford
Berkshire
RG17 0DN – UK
Tel: + 44 1488 680664